Evidence map›Paper›PMID 40440644›Full record

ArticleBiomolecules & biomedicine2025

Clinical significance of a novel inflammatory-nutritional index in glaucoma severity evaluation.

Xiao Xiao, Yanping Gao, Gao Zhang, Zuo Wang, An Li, Donghua Liu, Jing Fu, Wenbo Xiu, Chang Lu, Jinxia Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiao XiaoClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yanping GaoCore Laboratory, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Gao ZhangClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zuo WangDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
An LiClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Donghua LiuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Health Management Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Jing FuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Wenbo XiuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Chang LuDepartment of Electronic Communication and Technology, Shenzhen Institute of Information Technology, Shenzhen, China.
Jinxia WangClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xiong ZhuDepartment of Prenatal Diagnosis, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yang ChenClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Lingling ChenDepartment of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, China.
Bolin DengDepartment of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Ping ShuaiHealth Management Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Chong HeClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Medico-Engineering Cooperation on Applied Medicine Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Fang LuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Core Laboratory, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Medico-Engineering Cooperation on Applied Medicine Research Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the association between glaucoma and serum albumin (Alb), lymphocyte percentage (LYMPH%), and their combined index (LAP = LYMPH% × Alb), to evaluate their potential as biomarkers for systemic inflammation and disease progression in glaucoma. We enrolled 161 glaucoma patients and 181 healthy controls. Serum Alb and LYMPH% were measured using standard blood biochemistry and routine tests, and LAP was calculated accordingly. Statistical analyses were performed to compare these markers between groups and assess their correlation with disease severity. Both the median serum Alb level and peripheral blood LYMPH% were significantly lower in the glaucoma group compared to controls (Alb: 43.48 g/L vs 44.63 g/L, P < 0.001; LYMPH%: 24.25% vs 29.12%, P < 0.001). Correspondingly, LAP levels were also significantly reduced in glaucoma patients (1053 vs 1298, P < 0.001). Lower LYMPH% and LAP levels were associated with more severe glaucomatous visual impairment (LAP, healthy controls vs glaucoma: AUC = 0.7080, P < 0.001, Max Youden = 0.3621; early vs severe glaucoma: AUC = 0.8061, P < 0.001, Max Youden = 0.5377). In summary, LAP may serve as a supportive biomarker of systemic inflammation in glaucoma. It demonstrates good accuracy in reflecting glaucoma severity and shows potential for monitoring disease progression.

Indexed as

GlaucomaInflammationAgedBiomarkersCase-Control StudiesClinical RelevanceDisease ProgressionFemaleHumansLymphocytesMaleMiddle AgedSerum AlbuminSeverity of Illness IndexBiomarkersSerum Albumin

Identifiers

PMID40440644
PMCPMC12452127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.